SynthesisThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2026
Co-Occurrence of Inflammatory Bowel Disease in Patients with Vitiligo: A Systematic Review and Meta-Analysis.
Synthesis in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsInflammatory bowel disease (IBD) is a chronic, increasingly common condition linked to other autoimmune disorders, including vitiligo. This study aims to assess IBD co-occurrence in vitiligo patients to explore underlying immunogenetic factors and inform better screening and management. MATERIALS AND
methodsA systematic search was conducted across Scopus, PubMed/Medline, Web of Science, and Embase, to identify relevant studies published up to March 31, 2025. Studies examining the prevalence of IBD and its subtypes in patients with vitiligo wereincluded. Data were extracted and pooled using random effects models, with heterogeneity assessed through Cochran's Q test andHiggins I2 test.
resultsA total of 16 studies with 44 records were included in the analysis. The pooled prevalence of IBD was 0.97% (95% CI: 0.69-1.25),with Crohn's disease (CD) and ulcerative colitis (UC) reported at 0.45% (0.32-0.59) and 0.69% (0.42-0.97), respectively. Also, vitiligowas significantly associated with an increased risk of IBD (odds ratio [OR] = 1.51, 95% CI: 1.10-2.07), particularly for CD (OR = 1.49, 95%CI: 1.13-1.97). The pooled prevalence of IBD varied across countries, with the highest prevalence reported in Saudi Arabia. Additionally,women with vitiligo had a slightly higher pooled prevalence of IBD compared to men.
conclusionThis study found that the prevalence of IBD in patients with vitiligo is approximately 0.97%, with vitiligo significantly increasing the risk of developing IBD, particularly CD. Clinicians should consider IBD in the differential diagnosis of vitiligo patients withgastrointestinal symptoms. Cite this article as: Gu Z, Teng J. Co-occurrence of inflammatory bowel disease in patients with vitiligo: a systematic review and meta-analysis. Turk J Gastroenterol. 2026;37(1):3-14.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.